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Abstract
Hemodynamic instability frequently occurs in critically ill
patients. Pathophysiological rationale suggests that
hemodynamic monitoring (HM) may identify the
presence and causes of hemodynamic instability and
therefore may allow targeting therapeutic approaches.
However, there is a discrepancy between this
pathophysiological rationale to use HM and a paucity of
formal evidence (as defined by the strict criteria of
evidence-based medicine (EBM)) for its use. In this
editorial, we discuss that this paucity of formal evidence
that HM can improve patient outcome may be
explained by both the shortcomings of the EBM
methodology in the field of intensive care medicine
and the shortcomings of HM itself.
Hemodynamic monitoring (HM) plays a central role in the
care of critically ill patients, and yet the evidence that HM
improves patient outcome is either small or, more often,
non-existent [1, 2]. With the growing importance and influ-
ence of evidence-based medicine (EBM), it is imperative
that we better understand the reasons for, and implications
of, the absence of evidence for the way we use HM in the
intensive care unit (ICU) and in the operating room.
Since its introduction in 1992, EBM has become a “holy
grail” for rational clinical practice guided by scientific
clinical research findings. EBM was meant to initiate a para-
digm shift in clinical decision making which should be based
on “formal rules of evidence evaluating the clinical litera-
ture” [3]. EBM also defined a hierarchy of evidence, whereby
randomized controlled trials (RCTs) and systematic reviews
and meta-analyses of RCTs are regarded as superior to ani-
mal, in vitro or observational studies, case reports, and ex-
pert opinions [3, 4]. Advocates of EBM emphasize that it
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combines individual clinical experience with the best avail-
able external evidence from systematic research facilitating
decision making in the care of individual patients [4]. At the
same time, EBM, by its own definition, de-emphasizes the
importance of pathophysiologic rationale in making clinical
decisions [3]. Such de-emphasis is of special relevance to
HM monitoring in critical care and in anesthesia.
The hemodynamic status of critically ill patients is com-
plex; it may include varying degrees of hypovolemia, left
and right ventricular dysfunction, abnormalities of vascu-
lar tone, and microvascular dysfunction. These acute
cardiovascular impairments are often further complicated
by chronic co-morbidities. Physical examination and
conventional HM cannot adequately assess the nature and
extent of such hemodynamic dysfunction [5–7]. HM can
therefore be viewed as a means to minimize the uncer-
tainty that often surrounds the patient’s hemodynamic
status. This physiological reasoning stands behind the rec-
ommendations for the use of advanced HM in high-risk sur-
gical patients [8] and in critically ill patients in circulatory
shock [9–11]. The discrepancy between these recommenda-
tions and the weakness of the associated evidence indicates
that, in the absence of formal evidence as defined by the
strict criteria of EBM, the basis of clinical practice relies on
our best understanding of the underlying pathophysiological
processes that are associated with critical illness.
The lack of evidence behind our practice of HM may be
explained by the significant limitations of EBM. There is a
shortage of relevant, high-quality evidence that shows a
beneficial effect of any intervention on mortality in ICU
patients [12]. One of the reasons for the frequent negative
results of RCTs is the inclusion of heterogeneous patient
populations with a wide range of disease syndromes [2, 13].
Many RCTs are designed with a “one-size-fits-all”
approach, making the interventions potentially useful for
some patients but harmful for others (“misalignment”).
EBM has therefore been criticized for applying population-
derived data to individual patients whose unique situation
may be ignored. In the context of HM, some of the
“negative” studies on the pulmonary artery catheter (PAC)
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may have included patients in whom the information
provided by the PAC has been useful, while being mislead-
ing in others. Another pitfall of the “one-size-fits-all”
approach in HM is the determination of fixed “goals” of
resuscitation for a whole patient population, while disre-
garding the limitations and confounding factors of the
physiological variables (and their specific values) that have
been defined as goals [14]. These shortcomings of EBM in
intensive care may explain the “decline of truth” effect;
namely, that the original findings of “seminal” RCTs cannot
be replicated or are refuted by later studies [15]. These
significant inherent limitations of RCTs in ICU patients
may make them inferior to well-designed observational
studies for a variety of research questions [13].
However, the lack of evidence for our practice of HM
may also be due to the inherent limitations of HM itself.
First and foremost, the monitoring of physiological
variables per se cannot improve outcome unless it is
followed by correct therapeutic interventions. Making the
“correct” decision is not always straightforward even
when advanced HM is applied, due to the frequent
misinterpretation of the monitored parameters, the
failure to identify their relative importance, and the
remaining uncertainty regarding the exact nature of the
physiological impairment. The resulting variability of care
precludes the assessment of the value of that particular
monitoring modality per se by a formal RCT. In addition,
each hemodynamic variable has inherent limitations and
confounding factors. The monitoring of cardiac output
(CO), for instance, may be crucial in many instances of
hemodynamic instability. However, the CO value in and
by itself may not necessarily lead to the “correct” thera-
peutic decision, since the optimal CO cannot always be
determined: a high CO may not be high enough, and a
low CO does not tell us what to do (e.g., fluids, ino-
tropes?). The correct application of hemodynamic data
necessitates the integration of various variables that may
complement each other in order to provide the whole
clinical picture. On the other hand, such a multi-
parametric approach to decision making based on HM
may introduce another source of variability which can
further complicate any study design that is aimed at
establishing the value of HM in general, and of any
specific variable in particular. In addition, HM may
increase the tendency to normalize (or even maximize)
the measured physiological variables, although “normalcy”
of hemodynamic variables does not necessarily mean
“adequacy”. Last but not least, monitoring technologies
need to be meticulously validated with regard to their
measurement performance before they should be used in clin-
ical studies aiming to demonstrate an impact on outcome.
HM supplies invaluable insights about the patient’s
hemodynamic status and is essential for the correct
individual management of critically ill patients. The
paucity of formal evidence showing that HM is improv-
ing patient outcome may be explained by both the
shortcomings of EBM and HM itself. The honest and
open acknowledgement of these shortcomings should
become an integral part of the education of clinicians
who take care of critically ill patients.
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